CD73: A potential biomarker for anti-PD-1 therapy

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A(2A) blockade. Since CD73 is known to be overexpressed in several human cancers and A(2A) antagonists have undergone clinical trials for Parkinson's Disease, t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Beavis, Paul A, Slaney, Clare Y, Milenkovski, Nicole, Henderson, Melissa A, Loi, Sherene, Stagg, John, Kershaw, Michael H, Darcy, Phillip K
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2015
Aiheet:
Author's View
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589050/
https://ncbi.nlm.nih.gov/pubmed/26451321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046675
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia